CG Oncology, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CG Oncology, Inc. (CGON) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.33M, a 104.57% increase year-over-year.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.47M, a 25.68% increase year-over-year.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $7.33M, a 176.75% increase year-over-year.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.01M, a 211.98% increase year-over-year.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.68M, a 133.96% increase from fiscal 2024.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.40M, a 646.20% increase from fiscal 2023.
- CG Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.53M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.33M 10-Q · filed 2026-08-06 | $20.81M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $6.47M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $26.68M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $7.33M 10-Q · filed 2025-11-14 | $14.34M derived: sum of 2 quarters · filed 2026-08-06 | $19.49M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.01M 10-Q · filed 2026-08-06 | $12.16M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $5.15M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $11.40M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $2.65M 10-Q · filed 2025-11-14 | $4.89M derived: sum of 2 quarters · filed 2025-11-14 | $6.41M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $2.25M 10-Q · filed 2025-08-08 | $3.76M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $1.52M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $1.53M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $394.00K 10-Q · filed 2024-11-12 | $571.00K derived: sum of 2 quarters · filed 2024-11-12 | $750.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $177.00K 10-Q · filed 2024-11-12 | $356.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $179.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |